| Name | Title | Contact Details |
|---|
Educational Resource Systems is a Red Bank, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
In January 2014, Jordan Hospital joined the Beth Israel Deaconess Medical Center family of hospitals and become Beth Israel Deaconess Hospital-Plymouth. In 1899, a group of leading citizens from Plymouth saw a need to build a hospital to serve residents and pursued the idea of "a hospital on the hill". They approached retail tycon, philanthropist, and summer resident Eben Jordan, of the Jordan Marsh Company, and he donated $20,000 to build was was to become Jordan Hospital. In December 1903, Jordan Hospital opened its doors to the first patients and has remained a community hospital ever since. In 2014, Jordan Hospital become Beth Israel Deaconess Hospital-Plymouth and remains a private, not-for-profit hospital. We treat all patients, regardless of ability to pay. We proudly serve the communities of Bourne, Carver, Duxbury, Halifax, Kingston, Lakeville, Pembroke, Plympton, Plymouth, Marshfield, Middleboro, Sandwich and Wareham, as well as numerous visitors to our historic area. Beth Israel Deaconess-Plymouth is an affiliate of Beth Israel Deaconess Medical Center in Boston.
Peerbridge Health, Inc. is a mobile health IT company seeking to bring independence and precision with remote monitoring capabilities for medical, wellness and performance-based needs including the monitoring of vital signs, with thoughtful design and a seamless user experience.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.
At the Y, our cause is strengthening the foundations of community.